Cancer treatment has long faced a challenging trade-off: therapies strong enough to eliminate tumors often cause severe side effects. One promising solution involves cytokines, natural proteins that ...

Lung cancer among never-smokers is rising worldwide. In one U.S. study of 12,000 lung cancer patients, the share of people who didn’t smoke rose from 8 to 15 percent over twenty years.

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

Northwestern’s iSeg tool matches expert doctors and finds hidden cancer zones, with clinical rollout expected soon.

Kansas City, Kansas, residents are suing Harcros Chemicals, accusing the company of poisoning the air for decades with a “toxic cocktail” of emissions – leading to the deaths of ...

Researchers at McMaster University, Cleveland Clinic and Case Comprehensive Cancer Center have uncovered how a protein long ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

AstraZeneca PLC (AZN) and Summit Therapeutics Inc (SMMT) are reportedly discussing a $15 billion partnership to license the ...

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Long-term antihypertensive therapy was not associated with risk for cancer, cancer-related mortality or site-specific cancers ...